WO2015193359A2 - Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) - Google Patents
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) Download PDFInfo
- Publication number
- WO2015193359A2 WO2015193359A2 PCT/EP2015/063566 EP2015063566W WO2015193359A2 WO 2015193359 A2 WO2015193359 A2 WO 2015193359A2 EP 2015063566 W EP2015063566 W EP 2015063566W WO 2015193359 A2 WO2015193359 A2 WO 2015193359A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adenocarcinoma
- seq
- carcinoma
- class
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Definitions
- CLL chronic lymphoid leukemia
- the present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods.
- the present invention relates to the immunotherapy of cancer.
- the present invention furthermore relates to tumor- associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.
- CTL cytotoxic T cell
- the present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
- B-cell chronic lymphocytic leukemia also known as chronic lymphoid leukemia (CLL) is the most common type of leukemia.
- CLL cancers of the white blood cells (leukocytes).
- CLL affects B cell lymphocytes.
- B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies.
- B cells grow out of control and accumulate in the bone marrow and blood, where they crowd out healthy blood cells.
- CLL is a stage of small lymphocytic lymphoma (SLL), a type of B-cell lymphoma, which presents primarily in the lymph nodes.
- SLL and SLL are considered the same underlying disease, just with different appearances.
- CLL is a disease of adults, but, in rare cases, it can occur in teenagers and occasionally in children (inherited). Most (>75%) people newly diagnosed with CLL are over the age of 50, and the majority are men, with a median age of 70 years at the time of diagnosis. Though less common, CLL sometimes affects people between 30 and 39 years of age. The incidence of CLL increases very quickly with increasing age. In the United States, during 2012 about 16,060 new cases are expected to be diagnosed, and 4,580 patients are expected to die from CLL.
- CLL is very rare in Asian countries, such as Japan and China, and may account for as few as 10 percent of all leukemias in those regions.
- CLL chronic lymphoid leukemia
- the present invention employs peptides that stimulate the immune system of the patient and act as anti-tumor-agents in a non-invasive fashion.
- the present invention relates to a peptide comprising an amino acid sequence selected from the group of SEQ ID NO: 1 to SEQ ID NO: 225, SEQ ID NO: 226 to SEQ ID NO: 542 or SEQ ID NO: 543 to SEQ ID NO: 1016 or a variant sequence thereof which is at least 80%, preferably at least 90%, homologous (preferably at least 80% or at least 90% identical) to SEQ ID NO: 1 to SEQ ID NO: 225 or SEQ ID NO: 543 to SEQ ID NO: 1016, wherein said variant induces T cells cross-reacting with said peptide, or a pharmaceutical acceptable salt thereof, wherein said peptide is not the underlying full-length polypeptide.
- the present invention further relates to a peptide of the present invention comprising a sequence that is selected from the group SEQ ID NO: 1 to SEQ ID NO: 225, SEQ ID NO: 226 to SEQ ID NO: 542 or SEQ ID NO: 543 to SEQ ID NO: 1016 or a variant thereof, which is at least 80%, preferably at least 90%, homologous (preferably at least 80% or at least 90% identical) to SEQ ID NO: 1 to SEQ ID NO: 225 or SEQ ID NO: 543 to SEQ ID NO: 1016, wherein said peptide or variant thereof has an overall length for SEQ ID NO: 1 to SEQ ID NO: 225 of between 8 and 100, preferably between 8 and 30, and most preferred of between 8 and 14 amino acids, and for SEQ ID NO: SEQ ID NO: 543 to SEQ ID NO: 1016 of between 12 and 100, preferably between 12 and 30, and most preferred of between 12 to 18 amino acids.
- the following tables show the peptides according to the present invention, their respective SEQ ID NO:, and the prospective source (underlying) proteins for these peptides. All peptides in Table 1 a and 1 b bind to HLA A HLA B or HLA C alleles, peptides in Table 2 bind to HLA-DR alleles (MHC class II).
- the peptides in table 3 are further useful in the diagnosis and/or treatment of CLL, Acute myelogenous leukemia (AML), and other hematological malignancies, which involve an over- expression or over-presentaion of the respective underlying polypeptide.
- the present invention relates in particular to a peptide of the present invention comprising a sequence according to SEQ ID NO: 543 to SEQ ID NO: 1016 or a variant thereof, which is at least 80%, preferably at least 90%, homologous (preferably at least 80% or at least 90% identical) to SEQ ID NO: 543 to SEQ ID NO: 1016, wherein said peptide or variant thereof has an overall length of between 12 and 100, preferably between 12 and 30, and most preferred of between 12 to 18 amino acids.
- the present invention relates in particular to a peptide of the present invention consisting of the sequence according to SEQ ID NO: 543 to SEQ ID NO:
- LiTAAs HLA class I ligandome derived tumor associated antigens
- RASGRF1 Ras protein-specific guanine
- nucleotide-releasing factor 1 12 (40.0) B * 35
- HLA PARP3 poly (ADP-ribose) polymerase family Underlying source protein/ HLA ligands y [%]) HLA PARP3 poly (ADP-ribose) polymerase family,
- ARID5B AT rich interactive domain 5B (MRF1 - like) 7 (23.3)
- ERP44 endoplasmic reticulum protein 44 7 (23.3)
- VIAGNPAYRSFSN class II 648 VPQPEPETWEQILRRNVLQ class II
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HRP20200967TT HRP20200967T1 (hr) | 2014-06-20 | 2015-06-17 | Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll) |
| DK15730135.9T DK3157549T3 (da) | 2014-06-20 | 2015-06-17 | Hidtil ukendt immunterapi mod flere forskellige tumorer i blodet, navnlig kronisk lymfatisk leukæmi (CLL) |
| CA2950827A CA2950827A1 (en) | 2014-06-20 | 2015-06-17 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) |
| PL15730135T PL3157549T3 (pl) | 2014-06-20 | 2015-06-17 | Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL) |
| ES15730135T ES2802155T3 (es) | 2014-06-20 | 2015-06-17 | Inmunoterapia novedosa contra varios tumores de la sangre, en particular contra la leucemia linfoide crónica (LLC) |
| EP20170980.5A EP3708185A3 (en) | 2014-06-20 | 2015-06-17 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) |
| LTEP15730135.9T LT3157549T (lt) | 2014-06-20 | 2015-06-17 | Nauja imunoterapija prieš tam tikrus navikus, ypač lėtinę limfoidinę leukemiją (lll) |
| JP2016572509A JP6560261B2 (ja) | 2014-06-20 | 2015-06-17 | 数種の血液腫瘍、特に慢性リンパ性白血病（ｃｌｌ）に対する新規免疫療法 |
| EP15730135.9A EP3157549B1 (en) | 2014-06-20 | 2015-06-17 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) |
| RS20200910A RS60592B1 (sr) | 2014-06-20 | 2015-06-17 | Nova imunoterapija za lečenje nekoliko tumora krvi, posebno hronične limfocitne leukemije (hll) |
| SI201531301T SI3157549T1 (sl) | 2014-06-20 | 2015-06-17 | Nova imunoterapija proti številnim krvnim tumorjem, zlasti kronični limfoidni levkemiji (CLL) |
| US14/743,335 US10000533B2 (en) | 2014-06-20 | 2015-06-18 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US15/965,212 US10144763B2 (en) | 2014-06-20 | 2018-04-27 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/126,751 US10167317B1 (en) | 2014-06-20 | 2018-09-10 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/179,677 US10364271B2 (en) | 2014-06-20 | 2018-11-02 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/421,551 US10570175B2 (en) | 2014-06-20 | 2019-05-24 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/421,552 US10450346B2 (en) | 2014-06-20 | 2019-05-24 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/752,195 US10730910B2 (en) | 2014-06-20 | 2020-01-24 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
| US16/911,008 US10875892B2 (en) | 2014-06-20 | 2020-06-24 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014849P | 2014-06-20 | 2014-06-20 | |
| GBGB1411037.3A GB201411037D0 (en) | 2014-06-20 | 2014-06-20 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| US62/014,849 | 2014-06-20 | ||
| GB1411037.3 | 2014-06-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015193359A2 true WO2015193359A2 (en) | 2015-12-23 |
| WO2015193359A3 WO2015193359A3 (en) | 2016-02-25 |
Family
ID=51409910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2015/063566 Ceased WO2015193359A2 (en) | 2014-06-20 | 2015-06-17 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3708185A3 (enExample) |
| JP (1) | JP6560261B2 (enExample) |
| CA (1) | CA2950827A1 (enExample) |
| DK (1) | DK3157549T3 (enExample) |
| ES (1) | ES2802155T3 (enExample) |
| GB (1) | GB201411037D0 (enExample) |
| HU (1) | HUE050070T2 (enExample) |
| LT (1) | LT3157549T (enExample) |
| PL (1) | PL3157549T3 (enExample) |
| PT (1) | PT3157549T (enExample) |
| RS (1) | RS60592B1 (enExample) |
| SI (1) | SI3157549T1 (enExample) |
| TW (3) | TW202024125A (enExample) |
| WO (1) | WO2015193359A2 (enExample) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106046130A (zh) * | 2016-07-07 | 2016-10-26 | 胡国田 | 一种多肽及其应用 |
| WO2017140897A1 (en) * | 2016-02-19 | 2017-08-24 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers |
| WO2017153247A1 (en) * | 2016-03-08 | 2017-09-14 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| WO2017182395A1 (en) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| DE102016005550A1 (de) | 2016-05-09 | 2017-11-09 | Emc Microcollections Gmbh | Adjuvans zur lnduzierung einer zellulären lmmunantwort |
| WO2018037085A1 (en) * | 2016-08-26 | 2018-03-01 | Immatics Biotechnologies Gmbh | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| WO2018104407A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| US10055540B2 (en) | 2015-12-16 | 2018-08-21 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| WO2018189152A3 (en) * | 2017-04-10 | 2018-11-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| CN109593125A (zh) * | 2018-12-12 | 2019-04-09 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用 |
| WO2019162110A1 (en) * | 2018-02-21 | 2019-08-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| WO2020002063A1 (en) * | 2018-06-29 | 2020-01-02 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| EP3604327A1 (en) * | 2014-05-09 | 2020-02-05 | immatics Biotechnologies GmbH | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) |
| WO2020025576A1 (en) * | 2018-07-31 | 2020-02-06 | Immatics Biotechnologies Gmbh | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods |
| WO2020035123A1 (en) * | 2018-08-11 | 2020-02-20 | Baerlecken Niklas | Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis |
| US10702593B2 (en) | 2016-02-19 | 2020-07-07 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10934339B2 (en) | 2016-05-25 | 2021-03-02 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| US11264117B2 (en) | 2017-10-10 | 2022-03-01 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
| US11559550B2 (en) | 2017-04-10 | 2023-01-24 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| EP4317432A2 (en) | 2016-12-08 | 2024-02-07 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| US11897935B2 (en) | 2016-05-25 | 2024-02-13 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| US12084522B2 (en) | 2016-03-01 | 2024-09-10 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| US12202881B2 (en) | 2015-10-23 | 2025-01-21 | Jai Prakash | Integrin binding peptides and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (enExample) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US20030144474A1 (en) | 2000-06-05 | 2003-07-31 | Sunol Molecular Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US20040053292A1 (en) * | 2000-11-15 | 2004-03-18 | Jurg Tschopp | Proteins and dna sequences underlying these proteins used for treating inflammations |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2005114221A2 (en) * | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| PL1760088T3 (pl) | 2005-09-05 | 2008-10-31 | Immatics Biotechnologies Gmbh | Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| WO2012056407A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
-
2014
- 2014-06-20 GB GBGB1411037.3A patent/GB201411037D0/en not_active Ceased
-
2015
- 2015-06-17 LT LTEP15730135.9T patent/LT3157549T/lt unknown
- 2015-06-17 JP JP2016572509A patent/JP6560261B2/ja not_active Expired - Fee Related
- 2015-06-17 EP EP20170980.5A patent/EP3708185A3/en not_active Withdrawn
- 2015-06-17 PL PL15730135T patent/PL3157549T3/pl unknown
- 2015-06-17 CA CA2950827A patent/CA2950827A1/en not_active Abandoned
- 2015-06-17 RS RS20200910A patent/RS60592B1/sr unknown
- 2015-06-17 EP EP15730135.9A patent/EP3157549B1/en active Active
- 2015-06-17 SI SI201531301T patent/SI3157549T1/sl unknown
- 2015-06-17 PT PT157301359T patent/PT3157549T/pt unknown
- 2015-06-17 ES ES15730135T patent/ES2802155T3/es active Active
- 2015-06-17 HU HUE15730135A patent/HUE050070T2/hu unknown
- 2015-06-17 WO PCT/EP2015/063566 patent/WO2015193359A2/en not_active Ceased
- 2015-06-17 DK DK15730135.9T patent/DK3157549T3/da active
- 2015-06-18 TW TW109104580A patent/TW202024125A/zh unknown
- 2015-06-18 TW TW104119833A patent/TWI670282B/zh not_active IP Right Cessation
- 2015-06-18 TW TW108109176A patent/TW201930347A/zh unknown
Cited By (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604327A1 (en) * | 2014-05-09 | 2020-02-05 | immatics Biotechnologies GmbH | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) |
| US12202881B2 (en) | 2015-10-23 | 2025-01-21 | Jai Prakash | Integrin binding peptides and uses thereof |
| US10847253B2 (en) | 2015-12-16 | 2020-11-24 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| US10847252B2 (en) | 2015-12-16 | 2020-11-24 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| US11183286B2 (en) | 2015-12-16 | 2021-11-23 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
| US10055540B2 (en) | 2015-12-16 | 2018-08-21 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| US10702593B2 (en) | 2016-02-19 | 2020-07-07 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10702592B2 (en) | 2016-02-19 | 2020-07-07 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10933125B2 (en) | 2016-02-19 | 2021-03-02 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10813986B2 (en) | 2016-02-19 | 2020-10-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10363295B2 (en) | 2016-02-19 | 2019-07-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US10335475B2 (en) | 2016-02-19 | 2019-07-02 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| WO2017140897A1 (en) * | 2016-02-19 | 2017-08-24 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers |
| US10314898B2 (en) | 2016-02-19 | 2019-06-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| EP3885356A1 (en) * | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers |
| US10293036B2 (en) | 2016-02-19 | 2019-05-21 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US12084522B2 (en) | 2016-03-01 | 2024-09-10 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| US12103984B2 (en) | 2016-03-01 | 2024-10-01 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| EP4491191A3 (en) * | 2016-03-08 | 2025-04-09 | immatics biotechnologies GmbH | Uterine cancer treatments |
| WO2017153247A1 (en) * | 2016-03-08 | 2017-09-14 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US10239932B2 (en) | 2016-03-08 | 2019-03-26 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN109475596A (zh) * | 2016-03-08 | 2019-03-15 | 伊玛提克斯生物技术有限公司 | 子宫癌治疗 |
| US10669325B2 (en) | 2016-03-08 | 2020-06-02 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US10138287B2 (en) | 2016-03-08 | 2018-11-27 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US11390660B2 (en) | 2016-03-08 | 2022-07-19 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US12234276B2 (en) | 2016-03-08 | 2025-02-25 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| AU2017229149B2 (en) * | 2016-03-08 | 2021-09-16 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US12221467B2 (en) | 2016-03-08 | 2025-02-11 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US10266581B2 (en) | 2016-03-08 | 2019-04-23 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10464991B2 (en) | 2016-04-21 | 2019-11-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10435454B2 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10519216B2 (en) | 2016-04-21 | 2019-12-31 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10385111B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10640547B2 (en) | 2016-04-21 | 2020-05-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| WO2017182395A1 (en) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10385110B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| US10364281B2 (en) | 2016-04-21 | 2019-07-30 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| DE102016005550A1 (de) | 2016-05-09 | 2017-11-09 | Emc Microcollections Gmbh | Adjuvans zur lnduzierung einer zellulären lmmunantwort |
| US11897936B2 (en) | 2016-05-25 | 2024-02-13 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy |
| US10934339B2 (en) | 2016-05-25 | 2021-03-02 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| US11117951B2 (en) | 2016-05-25 | 2021-09-14 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| US11897935B2 (en) | 2016-05-25 | 2024-02-13 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| CN106046130A (zh) * | 2016-07-07 | 2016-10-26 | 胡国田 | 一种多肽及其应用 |
| US12221468B2 (en) | 2016-08-26 | 2025-02-11 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| WO2018037085A1 (en) * | 2016-08-26 | 2018-03-01 | Immatics Biotechnologies Gmbh | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10668100B1 (en) | 2016-08-26 | 2020-06-02 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| JP2024119949A (ja) * | 2016-08-26 | 2024-09-03 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| JP7504853B2 (ja) | 2016-08-26 | 2024-06-24 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| US10596196B2 (en) | 2016-08-26 | 2020-03-24 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10525084B2 (en) | 2016-08-26 | 2020-01-07 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| JP2019536426A (ja) * | 2016-08-26 | 2019-12-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| US12275776B2 (en) | 2016-08-26 | 2025-04-15 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10688131B2 (en) | 2016-08-26 | 2020-06-23 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10722536B1 (en) | 2016-08-26 | 2020-07-28 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10238691B1 (en) | 2016-08-26 | 2019-03-26 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US11058726B2 (en) | 2016-08-26 | 2021-07-13 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| EP3988563A3 (en) * | 2016-08-26 | 2022-07-27 | Immatics Biotechnologies GmbH | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10376542B2 (en) | 2016-08-26 | 2019-08-13 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10780125B2 (en) | 2016-08-26 | 2020-09-22 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| JP2022033740A (ja) * | 2016-08-26 | 2022-03-02 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| US11123370B2 (en) | 2016-08-26 | 2021-09-21 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| EP3504228A1 (en) * | 2016-08-26 | 2019-07-03 | Immatics Biotechnologies GmbH | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US10842817B2 (en) | 2016-08-26 | 2020-11-24 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| CN109803981A (zh) * | 2016-08-26 | 2019-05-24 | 伊玛提克斯生物技术有限公司 | 用于头颈鳞状细胞癌和其他癌症免疫治疗的新型肽和支架 |
| US10272114B1 (en) | 2016-08-26 | 2019-04-30 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| US12275775B2 (en) | 2016-08-26 | 2025-04-15 | Immatics Biotechnologies Gmbh | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
| EP4317432A2 (en) | 2016-12-08 | 2024-02-07 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| WO2018104407A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| US11135246B2 (en) | 2017-04-10 | 2021-10-05 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| WO2018189152A3 (en) * | 2017-04-10 | 2018-11-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| US11559550B2 (en) | 2017-04-10 | 2023-01-24 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| US10993963B2 (en) | 2017-04-10 | 2021-05-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| US10899819B2 (en) | 2017-04-10 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| US11264117B2 (en) | 2017-10-10 | 2022-03-01 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| US10888585B2 (en) | 2018-02-21 | 2021-01-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10792308B2 (en) | 2018-02-21 | 2020-10-06 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10888586B2 (en) | 2018-02-21 | 2021-01-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10874695B2 (en) | 2018-02-21 | 2020-12-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10888584B2 (en) | 2018-02-21 | 2021-01-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10888583B2 (en) | 2018-02-21 | 2021-01-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10888582B2 (en) | 2018-02-21 | 2021-01-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10894064B2 (en) | 2018-02-21 | 2021-01-19 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10898518B2 (en) | 2018-02-21 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10874696B2 (en) | 2018-02-21 | 2020-12-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10898519B2 (en) | 2018-02-21 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10905720B2 (en) | 2018-02-21 | 2021-02-02 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10905719B2 (en) | 2018-02-21 | 2021-02-02 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869890B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869895B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10993964B2 (en) | 2018-02-21 | 2021-05-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10993962B2 (en) | 2018-02-21 | 2021-05-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869894B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11013766B2 (en) | 2018-02-21 | 2021-05-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11013768B2 (en) | 2018-02-21 | 2021-05-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11013769B2 (en) | 2018-02-21 | 2021-05-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11020433B2 (en) | 2018-02-21 | 2021-06-01 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11020434B2 (en) | 2018-02-21 | 2021-06-01 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11026977B2 (en) | 2018-02-21 | 2021-06-08 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11033583B2 (en) | 2018-02-21 | 2021-06-15 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11033585B2 (en) | 2018-02-21 | 2021-06-15 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11040069B2 (en) | 2018-02-21 | 2021-06-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11052114B2 (en) | 2018-02-21 | 2021-07-06 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11052113B2 (en) | 2018-02-21 | 2021-07-06 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11058727B2 (en) | 2018-02-21 | 2021-07-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869893B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11065279B2 (en) | 2018-02-21 | 2021-07-20 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11103535B2 (en) | 2018-02-21 | 2021-08-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869892B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869891B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10869896B2 (en) | 2018-02-21 | 2020-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10813953B2 (en) | 2018-02-21 | 2020-10-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10799537B2 (en) | 2018-02-21 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11141437B2 (en) | 2018-02-21 | 2021-10-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers |
| US11147838B2 (en) | 2018-02-21 | 2021-10-19 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11147839B2 (en) | 2018-02-21 | 2021-10-19 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| WO2019162110A1 (en) * | 2018-02-21 | 2019-08-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11154576B2 (en) | 2018-02-21 | 2021-10-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| EP3755708A1 (en) * | 2018-02-21 | 2020-12-30 | immatics Biotechnologies GmbH | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11179418B2 (en) | 2018-02-21 | 2021-11-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11197892B2 (en) | 2018-02-21 | 2021-12-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10792307B2 (en) | 2018-02-21 | 2020-10-06 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10780123B2 (en) | 2018-02-21 | 2020-09-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11357797B2 (en) | 2018-02-21 | 2022-06-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11369636B2 (en) | 2018-02-21 | 2022-06-28 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11376281B2 (en) | 2018-02-21 | 2022-07-05 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10780122B2 (en) | 2018-02-21 | 2020-09-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10780124B2 (en) | 2018-02-21 | 2020-09-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10772915B2 (en) | 2018-02-21 | 2020-09-15 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10695377B2 (en) | 2018-02-21 | 2020-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10695373B2 (en) | 2018-02-21 | 2020-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10695376B2 (en) | 2018-02-21 | 2020-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10695374B2 (en) | 2018-02-21 | 2020-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11779606B2 (en) | 2018-02-21 | 2023-10-10 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11801264B2 (en) | 2018-02-21 | 2023-10-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10695375B2 (en) | 2018-02-21 | 2020-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| EP4321529A3 (en) * | 2018-02-21 | 2024-07-17 | immatics biotechnologies GmbH | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10751369B2 (en) | 2018-02-21 | 2020-08-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10709738B2 (en) | 2018-02-21 | 2020-07-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10709736B2 (en) | 2018-02-21 | 2020-07-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10709737B2 (en) | 2018-02-21 | 2020-07-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11918607B2 (en) | 2018-02-21 | 2024-03-05 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US11951132B2 (en) | 2018-02-21 | 2024-04-09 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| US10702553B2 (en) | 2018-02-21 | 2020-07-07 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| JP7579145B2 (ja) | 2018-06-29 | 2024-11-07 | イマティクス バイオテクノロジーズ ゲーエムベーハー | がんに対する免疫療法で使用するためのａ＊０３拘束性ペプチドおよび関連方法 |
| US12076379B2 (en) | 2018-06-29 | 2024-09-03 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| US11833193B2 (en) | 2018-06-29 | 2023-12-05 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| JP2021528046A (ja) * | 2018-06-29 | 2021-10-21 | イマティクス バイオテクノロジーズ ゲーエムベーハー | がんに対する免疫療法で使用するためのａ＊０３拘束性ペプチドおよび関連方法 |
| WO2020002063A1 (en) * | 2018-06-29 | 2020-01-02 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| US11872270B2 (en) | 2018-06-29 | 2024-01-16 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| US12202878B2 (en) | 2018-07-31 | 2025-01-21 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| US12195516B2 (en) | 2018-07-31 | 2025-01-14 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| US11655280B2 (en) | 2018-07-31 | 2023-05-23 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| US11655281B2 (en) | 2018-07-31 | 2023-05-23 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| US11603397B2 (en) | 2018-07-31 | 2023-03-14 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| WO2020025576A1 (en) * | 2018-07-31 | 2020-02-06 | Immatics Biotechnologies Gmbh | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods |
| US12084486B2 (en) | 2018-07-31 | 2024-09-10 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| US11732021B2 (en) | 2018-07-31 | 2023-08-22 | Immatics Biotechnologies Gmbh | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods |
| WO2020035123A1 (en) * | 2018-08-11 | 2020-02-20 | Baerlecken Niklas | Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis |
| CN109593125A (zh) * | 2018-12-12 | 2019-04-09 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3157549T3 (da) | 2020-06-22 |
| WO2015193359A3 (en) | 2016-02-25 |
| EP3157549A2 (en) | 2017-04-26 |
| JP2017525336A (ja) | 2017-09-07 |
| JP6560261B2 (ja) | 2019-08-14 |
| TW201613956A (en) | 2016-04-16 |
| ES2802155T3 (es) | 2021-01-15 |
| EP3708185A2 (en) | 2020-09-16 |
| HUE050070T2 (hu) | 2020-11-30 |
| GB201411037D0 (en) | 2014-08-06 |
| EP3157549B1 (en) | 2020-04-29 |
| RS60592B1 (sr) | 2020-08-31 |
| PT3157549T (pt) | 2020-07-01 |
| EP3708185A3 (en) | 2020-11-04 |
| CA2950827A1 (en) | 2015-12-23 |
| TW201930347A (zh) | 2019-08-01 |
| TWI670282B (zh) | 2019-09-01 |
| LT3157549T (lt) | 2020-08-10 |
| PL3157549T3 (pl) | 2020-12-14 |
| SI3157549T1 (sl) | 2020-08-31 |
| TW202024125A (zh) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10875892B2 (en) | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| EP3157549B1 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| US10286052B2 (en) | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | |
| CA3005813A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
| WO2019007974A1 (en) | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS | |
| EP3648790A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers | |
| US10925949B2 (en) | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | |
| CA3108747A1 (en) | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods | |
| JP2020014460A (ja) | 数種の血液腫瘍、特に慢性リンパ性白血病（ｃｌｌ）に対する新規免疫療法 | |
| HK40023054A (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
| HK40005505A (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
| HK1236424B (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| HK1236424A1 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| HK1232240B (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15730135 Country of ref document: EP Kind code of ref document: A2 |
|
| ENP | Entry into the national phase |
Ref document number: 2950827 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2016572509 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015730135 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2015730135 Country of ref document: EP |